Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1852W HIGH $3.10
Volume
1.82 M
Value Traded
5.05 M
Short % Float
10.03%
Days to Cover
8.2
+7.75%Week
+26.94%1 Month
-0.71%3 Month
-0.71%6 Month
-36.99%5 Year
-82.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
542.93 M
EPS (TTM)
-0.22
P/E Ratio
-
Ent. Value
381.51 M
Total Shares
195.30 M
Float Shares
180.88 M
Insiders
7.38%
Institutions
79.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
OVID Catalyst Timeline
Dated clinical, regulatory and corporate events for Ovid Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ovid Therapeutics Inc.
580Total events
18Upcoming
129Tier-1 (high impact)
2016 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Safety Data UpdateOV4071Clinical Data
No serious adverse events in OV4071 Phase 1 trial to date after multiple SAD/MAD cohorts
healthy volunteers (Phase 1)source ↗
●Quarterly UpdateCorporate
Ovid reports Q3 2026 financial results: cash $161.4M, net loss $20.8M
▲Trial InitiationOV329Trial
Initiated Phase 2 randomized, placebo-controlled study of OV329 in treatment-resistant FOS
treatment-resistant focal onset seizuressource ↗
▲Partnership / LicenseOV935FiledCorporate
Ovid and Takeda assigned global IP rights in soticlestat to NewCo launched by Perceptive Advisors
epilepsy (Dravet syndrome, DEEs)source ↗
◆Trial InitiationOV329Trial
Initiation of open-label proof-of-concept photo paroxysmal response study
focal onset seizuressource ↗
●Management ChangeCorporate
Strengthened executive leadership team with appointments of Kevin Norrett as CBO and Eliseo Salinas as Executive R&D Advisor
◆Oral PresentationPresentation
H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
◆Poster PresentationOV4071Presentation
Poster at APA Annual Meeting showcasing preclinical KCC2 work
psychosissource ↗
▲First Patient DosedOV4071Trial
First participant dosed with OV4071 in Phase 1 study
healthy volunteerssource ↗
◆Trial InitiationOV4071Trial
Potential initiation of proof-of-concept trial for first oral KCC2 direct activator OV4071
◆Trial InitiationOV329Trial
Potential initiation of Phase 2a patient study for OV329 in drug-resistant epilepsies
drug-resistant epilepsiessource ↗
◆IND SubmissionIND
IND submission for injectable KCC2 candidate expected in Q2 2026
CNS disorderssource ↗
▲Full ResultsOV329Clinical Data
Favorable safety, tolerability, PK and exposure from 7 mg and 9 mg dose cohorts
drug-resistant epilepsiessource ↗
▲Equity OfferingCorporate
Series A warrants exercised, resulting in proceeds of approximately $53.9 million
▲Topline ReadoutOV329Clinical Data
Topline safety, tolerability and PK findings from 7 mg dose cohort of OV329
refractory epilepsiessource ↗
▲IND ClearanceOV4071IND
HREC approval and CTN acknowledgement from Australian TGA for OV4071 Phase 1 trial
psychosis associated with Parkinson's disease and Lewy body dementiasource ↗
●IND SubmissionOV4071IND
Regulatory application submission for OV4071 Phase 1/1b study expected
psychosis associated with Parkinson's disease and Lewy body dementiasource ↗
◆Trial InitiationOV329Trial
Initiation of Phase 2a trial in adults with treatment-resistant focal onset seizures
drug-resistant epilepsiessource ↗
◆Trial InitiationOV4071Trial
Proof-of-mechanism trial for OV4071 expected to initiate in Q1 2026
CNS disorderssource ↗
▲Full ResultsOV350Clinical Data
Positive Phase 1 results for OV350 demonstrating first-ever clinical validation of direct KCC2 activation
neurological disorderssource ↗
▲Oral PresentationOV329Presentation
Presentation of OV329 biomarker results at AES 2025
epilepsysource ↗
▼Equity OfferingCorporate
Private placement totaling up to $175 million, initial closing of ~$81 million
▲Topline ReadoutOV329Clinical Data
Positive topline results from Phase 1 healthy volunteer study of OV329
drug-resistant epilepsiessource ↗
◆Oral PresentationPresentation
Ovid Therapeutics management to participate in BTIG Virtual Biotech Conference
◆Topline ReadoutOV329Clinical Data
Topline pharmacodynamic biomarker, safety and tolerability results from Phase 1 study of OV329
drug-resistant epilepsiessource ↗
▲Partnership / LicenseganaxoloneCorporate
Ovid sells future ganaxolone royalties to Immedica for $7M
CDKL5 deficiency disordersource ↗
◆R&D DayPresentation
Investor and media event on applying biomarkers in epilepsy, including OV329 program
▲Partnership / LicenseganaxoloneCorporate
Sale of worldwide ganaxolone royalty rights and licensing to Immedica Pharma AB for $7.0 million
◆Oral PresentationPresentation
Ovid Therapeutics to present at 24th Annual Needham Virtual Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How OVID actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-16 | OV4071 (Oral KCC2 activator) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 67%
Micro Cap(rank 450 of 671)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OV101 (gaboxadol) Small MoleculesCompletedNCT03697161 | Fragile X Syndrome (FXS) | Phase 2 | COMPLETED | 36 | Feb 26, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every OVID program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OV329 | drug-resistant epilepsies | Phase 2 | 2026-05-12 | favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses; 7 mg dose cohort of OV329; 9 mg dose cohort; no treatment-related serious adverse events observedRead More | Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Carter Charles RossOfficer (Chief Financial Officer) | Grant/Award | 50,000 94,375 held | $0.00 | 07/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OVID
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.2 % (-33.3 %) | 28.25 M | 10.50 M | -1.99% ( -213.03 K) |
Ownership Trends
OVID Short Interest
Shares sold short, counted twice a month.
10.03%
Short % of Float
of tradable shares sold short
18.1M
Shares Sold Short
+0.4% vs prior count
8.2 High
Days to Cover
trading days of normal volume to buy every short share back
2.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OVID ranks across every disease it competes in
Competitive Position is a premium feature
See how OVID ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOVID News
OVID▼ -0.7%today
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
Ovid Therapeutics reported significant progress in its clinical pipeline, including the advancement of OV329 in a Phase 2 focal epilepsy study and a pediatric formulation for TSC-associated seizures. The company also highlighted ongoing studies for OV4071, a KCC2 direct activator. Financially, Ovid holds $161.4 million in cash, ensuring operational stability into 2029.
Read more →OVID▼ -5.8%on this newsshared move
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics announced its participation in three upcoming investor conferences. The events include the Guggenheim Healthcare Innovation Conference on November 10, the Stifel Healthcare Conference on November 11, and the UBS European Healthcare Conference on November 16. Webcasts of the presentations will be accessible on the company's website.
Read more →OVIDOvid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics Inc. will participate in two upcoming investor conferences, the Cantor Global Healthcare Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 14. Webcasts of the presentations will be available on the company's website, along with archived replays for 30 days post-event. The company focuses on developing treatments for neurological disorders.
Read more →OVID▲ +6.9%on this news
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Ovid Therapeutics has reported significant business updates and financial results for Q2 2026, highlighting advancements in its clinical pipeline, including the Phase 1 study of OV4071 and the initiation of Phase 2 studies for OV329. The company has strengthened its leadership team and is positioned for potential future revenue from its interests in soticlestat. Despite a reported net loss, Ovid maintains a solid cash position to support ongoing operations.
Read more →OVIDOvid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics has announced several key executive appointments to enhance its leadership team. Kevin Norrett joins as Chief Business Officer, while Charles Carter is promoted to Chief Financial Officer. Eliseo Salinas becomes Executive R&D Advisor, and Victoria Fort is promoted to Chief Strategy Officer. These changes are aimed at supporting the company's ongoing development and strategic initiatives.
Read more →OVIDOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
Ovid Therapeutics has appointed Dr. Anna Greka to its Board of Directors, effective June 15, 2026. Dr. Greka, a renowned physician-scientist, brings over 25 years of experience in advancing biological discoveries into clinical-stage therapies. She will chair the newly formed Science and Technology Committee and contribute to the Compensation Committee.
Read more →OVIDOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Ovid Therapeutics reported positive business updates and financial results for Q1 2026, highlighting the initiation of a Phase 1 study for OV4071 and favorable results for OV329. The company plans to expand OV329's development into pediatric indications and has strengthened its financial position with significant capital raised. However, it also reported a net loss and increased expenses compared to the previous year.
Read more →OVIDOvid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Ovid Therapeutics will host a KCC2 Deep Dive R&D event on April 14, 2026, in New York. The event will showcase their first-in-class KCC2 portfolio, including direct activators for various neurological disorders. Leading experts will discuss pharmacodynamic data and the clinical development strategy. A live webcast will be available for participants.
Read more →OVID▲ +14.4%on this news· ran to +27% by day 3
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
Ovid Therapeutics announced a $60 million private placement financing expected to close on March 19, 2026. The funds will be used primarily to advance the development of OV329, a next-generation GABA-aminotransferase inhibitor, into additional indications such as tuberous sclerosis complex and infantile spasms. The transaction is led by Point72 and includes various other investors. The company will sell a total of 19,154,321 shares at $2.01 per share, plus warrants at a lower price. This financing is critical for addressing significant unmet medical needs in the field of brain disorders.
Read more →OVID▲ +14.4%on this news· ran to +27% by day 3
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Ovid Therapeutics has announced key developments, including new data for its GABA-AT inhibitor OV329, which shows favorable safety and tolerability, prompting plans for a Phase 2 trial in refractory epilepsies. The company is also expanding OV329's indication to include tuberous sclerosis complex seizures and infantile spasms, backed by a $60 million private placement. Additionally, OV4071, a novel oral KCC2 activator, has received clearance for its Phase 1 trial following approval from the Australian Therapeutic Goods Administration.
Read more →OVID▼ -9.5%on this news· ran to +22% by day 3
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Ovid Therapeutics has reported promising Phase 1 results for OV350, the first direct activator of the KCC2 transporter dosed in humans. The study successfully demonstrated safety, tolerability, and pharmacokinetics, prompting the company to advance its oral KCC2 direct activator programs. Ovid is now focusing on OV4071, expecting to initiate clinical studies in 2026. Despite the positive news, Ovid has decided not to continue developing OV350 in further clinical settings.
Read more →OVID▼ -13.3%on this news
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer. Dr. Kaufmann, with a strong background in CNS therapeutics and regulatory experience, will guide Ovid's clinical and medical strategies. Her expertise is expected to enhance the development of Ovid's pipeline, including the next-generation GABA-AT inhibitor, OV329.
Read more →OVIDOvid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid Therapeutics appointed Meg Alexander as CEO effective January 1, 2026, while Dr. Jeremy M. Levin transitions to Executive Chairman. The company completed a private placement raising up to $175 million, with an initial closing of approximately $81 million. This financing extends Ovid’s cash runway into the second half of 2028.
Read more →OVID▲ +12.2%on this news
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Ovid Therapeutics has announced a private placement financing expected to yield up to $175 million in gross proceeds. The financing includes participation from both new and existing investors and is set to close around October 6, 2025. Proceeds will be utilized for research and development, corporate expenses, and working capital needs.
Read more →OVID▲ +12.2%on this newsshared move
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
Ovid Therapeutics reported positive Phase 1 results for its experimental epilepsy drug OV329. The treatment showed strong inhibitory activity in healthy volunteers, with a 5 mg dose increasing inhibition by 53 percent. Safety data indicated a favorable profile with only mild, transient adverse events. The company plans to advance the drug into a Phase 2a study for drug-resistant focal onset seizures.
Read more →OVID▲ +56.9%on this news· ran to +71% by day 3
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Ovid Therapeutics has reported positive advancements in its clinical pipeline, including the upcoming Phase 1 readout for OV329, a GABA-AT inhibitor aimed at treating drug-resistant seizures. The company also plans to initiate a Phase 1/1b study for OV4071 in early 2026. Additionally, Ovid has strengthened its financial position through the sale of ganaxolone royalty rights, allowing for continued focus on its innovative small molecule therapies.
Read more →OVIDOvid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics Inc. will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company is dedicated to developing small molecule medicines for brain conditions with significant unmet needs. Their pipeline includes several promising candidates aimed at treating neurological and neuropsychiatric disorders.
Read more →OVIDOvid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Ovid Therapeutics has entered a definitive agreement with Immedica Pharma AB for the sale of future royalties related to ganaxolone outside of China. Immedica will pay $7 million to acquire these rights, providing Ovid with non-dilutive capital to support ongoing operations. The transaction does not impact Ovid's current pipeline, as the company is not pursuing further development of ganaxolone.
Read more →About Ovid Therapeutics Inc.
Headquarters441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001
BIOPHARMAWATCH ELITE
Trade the next OVID catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime